Share：
Share this content in WeChat
X
[Chinese][PDF]3506
• Clinical Article •
Predicting the efficacy of neoadjuvant chemotherapy for breast cancer by combining hormone receptor and human epidermal growth factor receptor 2 with ADC maximum
LI Zhifan  LIU Xinran  WANG Ziyuan  FENG Wen  LEI Junqiang 

Cite this article as: LI Z F, LIU X R, WANG Z Y, et al. Predicting the efficacy of neoadjuvant chemotherapy for breast cancer by combining hormone receptor and human epidermal growth factor receptor 2 with ADC maximum[J]. Chin J Magn Reson Imaging, 2023, 14(10): 71-77. DOI:10.12015/issn.1674-8034.2023.10.013.


[Abstract] Objective To construct a nomogram based on MRI and clinicopathological indicators of breast cancer for early prediction of pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer patients.Materials and Methods A total of 82 breast cancer patients who underwent NAC and subsequent surgery at the First Hospital of Lanzhou University from January 2021 to October 2022 were retrospectively analyzed. Imaging and clinicopathological data of patients prior to NAC were collected. All patients underwent MRI scanning program before surgery. First, a univariate logistic regression analysis was performed to screen out the predictors associated with pCR. Multivariate logistic regression analysis was then performed to finally screen out the independent predictors of pCR. The independent predictors were used to construct a nomogram model for predicting pCR after NAC for breast cancer. Bootstrap was used for internal validation and calibration of models. The ROC curve was drawn to evaluate the diagnostic efficacy of the model, and the clinical application value of the model was evaluated by the decision curve analysis (DCA).Results This study showed that progesterone receptor (PR) state (P=0.04), human epidermal growth factor receptor 2 (HER-2) state (P＜0.01), and maximum apparent diffusion coefficient (ADCmax) (P=0.03) were independent predictors of pCR. The area under the ROC curve of the nomogram was 0.86. The calibration plot showed a high degree of agreement between the nomogram prediction probability and the actual pCR probability. Decision curve analysis showed that the nomogram model had good clinical application value. The corrected concordance index (C-index) for internal verification by the Bootstrap method was 0.84.Conclusions The nomogram model is helpful in predicting the pCR after NAC for breast cancer, which was constructed based on HER-2 status, PR status and ADCmax value, so as to realize personalized diagnosis and treatment of patients and improve their prognosis.
[Keywords] breast cancer；neoadjuvant chemotherapy；pathological complete response；nomogram；magnetic resonance imaging

LI Zhifan1   LIU Xinran1   WANG Ziyuan1   FENG Wen1   LEI Junqiang1, 2*  

1 The First Clinical Medical College, Lanzhou University, Lanzhou 730000, China

2 Department of Radiology, the First Hospital of Lanzhou University, Lanzhou 730000, China

Corresponding author: LEI J Q, E-mail: leijq2011@126.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Gansu Province Education Science and Technology Innovation Project (No. 2022B-025).
Received  2023-06-19
Accepted  2023-09-14
DOI: 10.12015/issn.1674-8034.2023.10.013
Cite this article as: LI Z F, LIU X R, WANG Z Y, et al. Predicting the efficacy of neoadjuvant chemotherapy for breast cancer by combining hormone receptor and human epidermal growth factor receptor 2 with ADC maximum[J]. Chin J Magn Reson Imaging, 2023, 14(10): 71-77. DOI:10.12015/issn.1674-8034.2023.10.013.

[1]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]
KORDE L A, SOMERFIELD M R, CAREY L A, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline[J]. J Clin Oncol, 2021, 39(13): 1485-1505. DOI: 10.1200/JCO.20.03399.
[3]
ABDEL-RAZEQ H, KHALIL H, ASSI H I, et al. Treatment strategies for residual disease following neoadjuvant chemotherapy in patients with early-stage breast cancer[J]. Curr Oncol, 2022, 29(8): 5810-5822. DOI: 10.3390/curroncol29080458.
[4]
ZHU X L, SHEN J, ZHANG H L, et al. A novel combined nomogram model for predicting the pathological complete response to neoadjuvant chemotherapy in invasive breast carcinoma of No specific type: real-world study[J/OL]. Front Oncol, 2022, 12: 916526 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/35734603/. DOI: 10.3389/fonc.2022.916526.
[5]
LIU W F, CHEN W, ZHANG X X, et al. Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin[J/OL]. Sci Rep, 2021, 11(1): 199 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/33420241/. DOI: 10.1038/s41598-020-80415-w.
[6]
WANG B C, FU C, XIE L K, et al. Comparative toxicities of neoadjuvant chemotherapy with or without bevacizumab in HER2-negative breast cancer patients: a meta-analysis[J]. Ann Pharmacother, 2020, 54(6): 517-525. DOI: 10.1177/1060028019895783.
[7]
DONG J M, WANG H X, ZHONG X F, et al. Changes in background parenchymal enhancement in HER2-positive breast cancer before and after neoadjuvant chemotherapy: association with pathologic complete response[J/OL]. Medicine, 2018, 97(43): e12965 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/30412117/. DOI: 10.1097/MD.0000000000012965.
[8]
PENNISI A, KIEBER-EMMONS T, MAKHOUL I, et al. Relevance of pathological complete response after neoadjuvant therapy for breast cancer[J/OL]. Breast Cancer, 2016, 10: 103-106 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/27478380/. DOI: 10.4137/BCBCR.S33163.
[9]
CHO H H, PARK M, PARK H, et al. The tumor-fat interface volume of breast cancer on pretreatment MRI is associated with a pathologic response to neoadjuvant chemotherapy[J/OL]. Biology, 2020, 9(11): 391 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/33182628/. DOI: 10.3390/biology9110391.
[10]
Chinese Anti-Cancer Association, Committee of Breast Cancer Society. Guidelines and norms for diagnosis and treatment of breast cancer of China Anti-Cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040. DOI: 10.19401/j.cnki.1007-3639.2021.10.013.
[11]
TAYDAŞ O, DURHAN G, AKPıNAR M G, et al. Comparison of MRI and US in tumor size evaluation of breast cancer patients receiving neoadjuvant chemotherapy[J]. Eur J Breast Health, 2019, 15(2): 119-124. DOI: 10.5152/ejbh.2019.4547.
[12]
CHEN X Y, HE C, HAN D D, et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis[J]. Future Oncol, 2017, 13(9): 843-857. DOI: 10.2217/fon-2016-0420.
[13]
HAYASHI M, YAMAMOTO Y, IWASE H. Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer[J/OL]. Chin Clin Oncol, 2020, 9(3): 31 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/32594748/. DOI: 10.21037/cco-20-15.
[14]
SHUAI Y J, MA L. Prognostic value of pathologic complete response and the alteration of breast cancer immunohistochemical biomarkers after neoadjuvant chemotherapy[J]. Pathol Res Pract, 2019, 215(1): 29-33. DOI: 10.1016/j.prp.2018.11.003.
[15]
GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2020, 18(4): 452-478. DOI: 10.6004/jnccn.2020.0016.
[16]
HAMMOND M E, HAYES D F, WOLFF A C, et al. American society of clinical oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J]. J Oncol Pract, 2010, 6(4): 195-197. DOI: 10.1200/JOP.777003.
[17]
WOLFF A C, HAMMOND M E H, ALLISON K H, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of American pathologists clinical practice guideline focused update[J]. J Clin Oncol, 2018, 36(20): 2105-2122. DOI: 10.1200/JCO.2018.77.8738.
[18]
NIELSEN T O, LEUNG S C Y, RIMM D L, et al. Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in breast cancer working group[J]. J Natl Cancer Inst, 2021, 113(7): 808-819. DOI: 10.1093/jnci/djaa201.
[19]
OGSTON K N, MILLER I D, PAYNE S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival[J]. Breast, 2003, 12(5): 320-327. DOI: 10.1016/s0960-9776(03)00106-1.
[20]
Writing Group of Expert Panel Consensus on Pathological Diagnosis of Breast Cancer With Neoadjuvant Therapy, The 2020 Version. Expert panel consensus on pathological diagnosis of breast cancer with neoadjuvant therapy, the 2020 version[J]. Chin J Pathol, 2020, 49(4): 296-298, 299. DOI: 10.3760/cma.j.cn112151-20200102-00007.
[21]
LIANG X H, CHEN X F, YANG Z Q, et al. Early prediction of pathological complete response to neoadjuvant chemotherapy combining DCE-MRI and apparent diffusion coefficient values in breast Cancer[J/OL]. BMC Cancer, 2022, 22(1): 1250 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/36460972/. DOI: 10.1186/s12885-022-10315-x.
[22]
MATSUDA M, FUKUYAMA N, MATSUDA T, et al. Utility of synthetic MRI in predicting pathological complete response of various breast cancer subtypes prior to neoadjuvant chemotherapy[J]. Clin Radiol, 2022, 77(11): 855-863. DOI: 10.1016/j.crad.2022.06.019.
[23]
LIAN X, GUO D Q, QIAN L X. Characteristics of breast background parenchymal enhancement on MRI before and after neoadjuvant chemotherapy in patients with HER2 positive breast cancer[J]. Radiol Pract, 2022, 37(6): 723-728. DOI: 10.13609/j.cnki.1000-0313.2022.06.009.
[24]
RELLA R, BUFI E, BELLI P, et al. Association between background parenchymal enhancement and tumor response in patients with breast cancer receiving neoadjuvant chemotherapy[J]. Diagn Interv Imaging, 2020, 101(10): 649-655. DOI: 10.1016/j.diii.2020.05.010.
[25]
OH S J, CHAE E Y, CHA J H, et al. Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy[J/OL]. Br J Radiol, 2018, 91(1088): 20170550 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/29848015/. DOI: 10.1259/bjr.20170550.
[26]
ZHAO M J, ZHAO L H, YANG H, et al. Apparent diffusion coefficient for the prediction of tumor response to neoadjuvant chemo-radiotherapy in locally advanced rectal cancer[J/OL]. Radiat Oncol, 2021, 16(1): 17 [2023-06-18]. https://pubmed.ncbi.nlm.nih.gov/33472660/. DOI: 10.1186/s13014-020-01738-6.
[27]
HAHN S Y, KO E Y, HAN B K, et al. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy[J]. Eur J Radiol, 2014, 83(2): 283-288. DOI: 10.1016/j.ejrad.2013.10.023.
[28]
HORVAT J V, BERNARD-DAVILA B, HELBICH T H, et al. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer[J]. J Magn Reson Imaging, 2019, 50(3): 836-846. DOI: 10.1002/jmri.26697.
[29]
ESSERMAN L J, BERRY D A, DEMICHELE A, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL: CALGB 150007/150012, ACRIN 6657[J]. J Clin Oncol, 2012, 30(26): 3242-3249. DOI: 10.1200/JCO.2011.39.2779.
[30]
ALBA E, ALBANELL J, DE LA HABA J, et al. Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial[J]. Br J Cancer, 2014, 110(5): 1139-1147. DOI: 10.1038/bjc.2013.831.
[31]
VAN MACKELENBERGH M T, DENKERT C, NEKLJUDOVA V, et al. Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials[J]. Breast Cancer Res Treat, 2018, 167(1): 59-71. DOI: 10.1007/s10549-017-4480-5.
[32]
SYMMANS W F, YAU C, CHEN Y Y, et al. Assessment of residual cancer burden and event-free survival in neoadjuvant treatment for high-risk breast cancer: an analysis of data from the I-SPY2 randomized clinical trial[J]. JAMA Oncol, 2021, 7(11): 1654-1663. DOI: 10.1001/jamaoncol.2021.3690.
[33]
HAQUE W, VERMA V, HATCH S, et al. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy[J]. Breast Cancer Res Treat, 2018, 170(3): 559-567. DOI: 10.1007/s10549-018-4801-3.
[34]
GOORTS B, VAN NIJNATTEN T J, MUNCK L D, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients[J]. Breast Cancer Res Treat, 2017, 163(1): 83-91. DOI: 10.1007/s10549-017-4155-2.
[35]
LÜ Y L, LI Y, MU W M, et al. Factors affecting pathological complete response after neoadjuvant chemotherapy in operable primary breast cancer[J]. J Coll Physicians Surg Pak, 2020, 30(4): 389-393. DOI: 10.29271/jcpsp.2020.04.389.
[36]
JAIN P, DOVAL DC, BATRA U, et al. Ki-67 labeling index as a predictor of response to neoadjuvant chemotherapy in breast cancer[J]. Jpn J Clin Oncol, 2019, 49(4): 329-338. DOI: 10.1093/jjco/hyz012.
[37]
CHEN R, YE Y, YANG C, et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients[J]. Breast Cancer Res Treat, 2018, 170(1): 35-43. DOI: 10.1007/s10549-018-4730-1.

PREV Application value of 3.0 T MAGIC relaxation time quantitative technique in neonates with acute bilirubin encephalopathy
NEXT Application value of synthetic MRI in the differential diagnosis of benign and malignant breast lesions with peripheral rim enhancement
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn